{"nctId":"NCT00593450","briefTitle":"Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial","startDateStruct":{"date":"2008-02","type":"ACTUAL"},"conditions":["Age Related Macular Degeneration"],"count":1208,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ranibizumab"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: ranibizumab"]},{"label":"4","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab"]}],"interventions":[{"name":"ranibizumab","otherNames":["Lucentis"]},{"name":"bevacizumab","otherNames":["Avastin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Active, subfoveal choroidal neovascularization (CNV)\n* Fibrosis \\< 50% of total lesion area\n* Visual acuity (VA) 20/25-20/320\n* Age ≥ 50 yrs\n* At least 1 drusen (\\>63μ) in either eye or late AMD in fellow eye\n\nExclusion Criteria:\n\n* Previous treatment for CNV in study eye\n* Other progressive retinal disease likely to compromise VA\n* Contraindications to injections with Lucentis or Avastin","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline Visual-acuity Score (Frequency)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"71","spread":null},{"groupId":"OG003","value":"76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"98","spread":null},{"groupId":"OG002","value":"103","spread":null},{"groupId":"OG003","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"75","spread":null},{"groupId":"OG003","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Visual-acuity Score (Continuous)","description":"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly. The VA score change is the difference of the VA score at 1 Year and the VA score at baseline.\n\nIn this study, the outcome VA score change is ranged from -71 to 52, with the higher VA score change the better visual acuity improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"14.1"},{"groupId":"OG001","value":"8.0","spread":"15.8"},{"groupId":"OG002","value":"6.8","spread":"13.1"},{"groupId":"OG003","value":"5.9","spread":"15.7"}]}]}]},{"type":"SECONDARY","title":"Visual-acuity Score and Snellen Equivalent (Frequency)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"38","spread":null},{"groupId":"OG003","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"134","spread":null},{"groupId":"OG002","value":"141","spread":null},{"groupId":"OG003","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"23","spread":null},{"groupId":"OG003","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"17","spread":null},{"groupId":"OG003","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Visual-acuity Score and Snellen Equivalent (Continuous)","description":"Visual acuity testing was performed with the Electronic Visual Tester (EVA) following the ETDRS protocol. VA score is measured as number of letters read correctly.\n\nIn this study, the outcome VA score is ranged from 0 to 97, with the higher score the better visual acuity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":"17.7"},{"groupId":"OG001","value":"68.4","spread":"18.2"},{"groupId":"OG002","value":"68.4","spread":"16.4"},{"groupId":"OG003","value":"66.5","spread":"19.0"}]}]}]},{"type":"SECONDARY","title":"Number of Treatments","description":"Cumulative over the 1 year of trial","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"1.5"},{"groupId":"OG001","value":"11.9","spread":"1.2"},{"groupId":"OG002","value":"6.9","spread":"3.0"},{"groupId":"OG003","value":"7.7","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Average Cost of Drug/Patient","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23400","spread":"3000"},{"groupId":"OG001","value":"595","spread":"60"},{"groupId":"OG002","value":"13800","spread":"6000"},{"groupId":"OG003","value":"385","spread":"175"}]}]}]},{"type":"SECONDARY","title":"Total Thickness at Fovea","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"266","spread":"125"},{"groupId":"OG001","value":"300","spread":"149"},{"groupId":"OG002","value":"294","spread":"139"},{"groupId":"OG003","value":"308","spread":"127"}]}]}]},{"type":"SECONDARY","title":"Total Thickness Change From Baseline at Fovea","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-196","spread":"176"},{"groupId":"OG001","value":"-164","spread":"181"},{"groupId":"OG002","value":"-168","spread":"186"},{"groupId":"OG003","value":"-152","spread":"178"}]}]}]},{"type":"SECONDARY","title":"Retinal Thickness Plus Subfoveal-fluid Thickness at Fovea","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":"57"},{"groupId":"OG001","value":"172","spread":"81"},{"groupId":"OG002","value":"166","spread":"66"},{"groupId":"OG003","value":"172","spread":"68"}]}]}]},{"type":"SECONDARY","title":"Retinal Thickness Plus Subfoveal-fluid Thickness Change From Baseline at Fovea","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-100","spread":"130"},{"groupId":"OG001","value":"-79","spread":"132"},{"groupId":"OG002","value":"-81","spread":"134"},{"groupId":"OG003","value":"-79","spread":"123"}]}]}]},{"type":"SECONDARY","title":"Fluid on Optical Coherence Tomography","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"68","spread":null},{"groupId":"OG003","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"188","spread":null},{"groupId":"OG002","value":"203","spread":null},{"groupId":"OG003","value":"214","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Dye Leakage on Angiogram","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167","spread":null},{"groupId":"OG001","value":"153","spread":null},{"groupId":"OG002","value":"133","spread":null},{"groupId":"OG003","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"137","spread":null},{"groupId":"OG003","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Area of Lesion","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"6.8"},{"groupId":"OG001","value":"6.5","spread":"6.7"},{"groupId":"OG002","value":"7.3","spread":"6.5"},{"groupId":"OG003","value":"7.0","spread":"7.5"}]}]}]},{"type":"SECONDARY","title":"Area of Lesion Change From Baseline","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"5.2"},{"groupId":"OG001","value":"0.3","spread":"4.9"},{"groupId":"OG002","value":"0.6","spread":"6.2"},{"groupId":"OG003","value":"1.3","spread":"6.6"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic Blood Pressure From Baseline","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"22.4"},{"groupId":"OG001","value":"-5.4","spread":"18.2"},{"groupId":"OG002","value":"-5.2","spread":"20.3"},{"groupId":"OG003","value":"-4.5","spread":"20.0"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure From Baseline","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"11.9"},{"groupId":"OG001","value":"-1.4","spread":"11.2"},{"groupId":"OG002","value":"-1.9","spread":"10.2"},{"groupId":"OG003","value":"-2.1","spread":"10.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":53,"n":301},"commonTop":["Endophthalmitis","Pseudoendophthalmitis"]}}}